$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Is aletinib, the killer weapon against lung cancer, effective?
2025-10-19 11:44:20
Check Details
Safety Trial Status of Crizotinib/Xalkori in Patients with Lung Cancer
2025-10-19 11:44:20
Check Details
Crizotinib in the treatment of advanced non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Efficacy and safety data of crizotinib (Xalkori) in non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Safety and tolerability of crizotinib in the treatment of positive non-small cell lung cancer_ Kanghule
2025-10-19 11:44:20
Check Details
Targeted drug for the treatment of ROS1 rearranged lung cancer: Crizotinib
2025-10-19 11:44:20
Check Details
Crizotinib is highly effective against ROS1 rearrangement in advanced non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Crizotinib is a targeted drug for the treatment of patients with ROS1-positive advanced lung cancer
2025-10-19 11:44:20
Check Details
First-line treatment for ALK-positive lung cancer-crizotinib
2025-10-19 11:44:20
Check Details
Research progress of Lorlatinib in ALK-positive lung cancer
2025-10-19 11:44:20
Check Details
The third generation ALK/ROS1 mutated lung cancer targeting drug: lorlatinib
2025-10-19 11:44:20
Check Details
Analysis of efficacy and adverse reactions of lorlatinib in the first-line treatment of ALK-positive lung cancer
2025-10-19 11:44:20
Check Details
1
2
...
9961
9962
9963
9964
9965
9966
9967
...
10234
10235
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Belumosudil for cGVHD: 200mg with Food, Pregnancy Contraception, Liver Monitoring, Drug Interactions
2
Elagolix GnRH Antagonist for Endometriosis Pain: Mechanism, Dosing, Bone and Mood Safety
3
Diazoxide Oral Suspension Inadequate Response: Glucose-Based Titration, Stop at 2–3 Weeks, Re-evaluate Hypoglycemia Cause
4
Ambrisentan Adjunct for IgA Nephropathy Proteinuria: ETA Mechanism, Real-World Evidence, Safety Monitoring
5
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
6
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
7
Lemborexant for Insomnia: Dual Orexin 5/10mg, 7-Hour Bedtime, 7–10-Day Review and Safety
8
Fayuvi (rebisufligene etisparvovec-hopf) for MPS IIIA: AAV9 Single Infusion, Weight-Based Dose, Steroids, Liver/Platelet Monitoring
9
Trelagliptin Once-Weekly DPP-4 for Type 2 Diabetes: Dosing, Renal Adjustment, Discontinuation
10
Orforglipron (Foundayo) vs Metformin: Oral GLP-1 Weight Loss and T2D Use
11
Fayuvi (rebisufligene etisparvovec-hopf/UX111) for MPS IIIA: AAV9 SGSH Gene Therapy, Cognition, and Safety
12
Ramosetron Hydrochloride Orally Disintegrating Tablets: A 5-HT3 Receptor Antagonist for Diarrhea-Predominant IBS